High NETs signature group patients exhibit a significant presence of anti-tumor immune cells in the TME, such as NK cells (Myers et al., 2021; Tang et al., 2023), CD8+ T cells (Virassamy et al., 2023), and CD4+ T cells (Li et al., 2024). This evidence concerns the gene CD8A and neoplasm.